ASP Isotopes Provides Business Updates

ASP Isotopes Provides Business Updates GlobeNewswire October 13, 2025 WASHINGTON, Oct. 13, 2025 (GLOBE NEWSWIRE) — ASP Isotopes Inc. NASDAQ: ASPI (“ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a business development update, including […]

Evolution Petroleum to Present at the LD Micro Main Event XIX

Evolution Petroleum to Present at the LD Micro Main Event XIX GlobeNewswire October 13, 2025 HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) — Evolution Petroleum Corporation (NYSE American: EPM) (“Evolution” or the “Company”) today announced that its management team will participate in the upcoming LD Micro Main Event Conference on October 19-21, 2025, at the Hotel

Flux Capital, Led by Ari Stiegler, Wins “Allocator One Breakout Fund of the Year”

Flux Capital, a leading venture capital fund founded by Los Angeles investor Ari Stiegler, today announced it has been named Allocator One's “Breakout Fund of the Year.” The honor follows a competitive review of hundreds of emerging managers on the Allocator One platform and underscores Flux Capital's strong track record in portfolio construction, rigorous risk

Investors Back Irys Insurtech with $12.5 Million to Reinvent Insurance Software

Irys's AI-native operating system replaces decades-old systems with scalable, intelligent technology -signaling a new era for insurance distribution modernization and investor confidence in the sector. Irys, the company rebuilding insurance infrastructure from the ground up, today announced a $12.5 million seed round led by Markd, with participation from Deepwork Capital, Florida Opportunity Fund, Ansay &

ABRDN GLOBAL INFRASTRUCTURE INCOME FUND (ASGI) ANNOUNCES CLOSING AND REORGANIZATION OF ABRDN JAPAN EQUITY FUND, INC. (JEQ)

abrdn Global Infrastructure Income Fund (NYSE: ASGI) (“ASGI” or the “Acquiring Fund) and abrdn Japan Equity Fund, Inc. (NYSE: JEQ) (“JEQ” or the “Acquired Fund”), announce today the completed reorganization of the Acquired Fund with the Acquiring Fund after close of business on October 10, 2025. https://mma.prnewswire.com/media/2698388/Aberdeen_Investments_Logo.jpg In the reorganization, common shareholders of JEQ received

Coveo Achieves AWS Generative AI Competency

Coveo, the leader in AI-Relevance, delivering best-in-class AI-search and generative experiences that maximize business outcomes at every point-of-experience, today announced that it has achieved the Amazon Web Services (AWS) Generative AI Competency. This specialization recognizes Coveo as an AWS Partner that helps customers and the AWS Partner Network (APN) drive the advancement of services, tools,

Cetera Welcomes 34-Member Pillar Financial Group with $1.8 Billion in Client Assets

Multigenerational advisory firm with offices in Washington, Idaho, and Illinois joins Cetera for its technology, personalized service, and commitment to supporting independent financial advisors Cetera today announced the addition of Pillar Financial Group, led by seven partners including CEO Luke Madsen, CFP®, CLU®, and a 34-member advisory team. The Seattle-based firm brings approximately $1.8 billion

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

(NasdaqGM:MNKD), If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026 WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq: MNKD)

Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit

NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that members of its leadership team will participate in the 8th Annual Targeted Protein Degradation (TPD) & Induced Proximity Summit, taking place October 27-30, 2025 in Boston,

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes GlobeNewswire October 13, 2025 If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapy sBLA submission based on data

Scroll to Top